AVIR Atea Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Atea Pharmaceuticals is trading 5.4% down today amid broad market retreat led by technology shares
Atea Pharmaceuticals is trading at $4.22, with a -5.38% change, as technology shares lead a sharp market-wide retreat. - Reports cite concerns about AI...
🟢 Atea Pharmaceuticals is trading 5% up on November 4, 2026, as major U.S. indexes rise
Atea Pharmaceuticals is trading at $4.38, up +5.04%, alongside a strong broader-market session. - Major U.S. indexes are higher; no clear company-specific...
🟢 Atea Pharmaceuticals is trading 5% up today as biotech ETF XBI rose 2.13%
Atea Pharmaceuticals is trading 5% higher at $4.30 on November 3, 2026, alongside biotech-sector strength; available reports did not identify a new...
🔴 Atea Pharmaceuticals is trading 5% down with no clear company-specific catalyst
Atea Pharmaceuticals is trading at $4.24, down 5.04%, with no clear company-specific catalyst identified. - Atea Pharmaceuticals’ investor-relations news page...
🔴 Atea Pharmaceuticals is trading 5% down today as hotter-than-expected CPI renews rate concerns
Atea Pharmaceuticals is trading 5% down at $4.73 on October 14, 2026, as biotech and broader markets weaken amid renewed interest-rate concerns following...
🔴 Atea Pharmaceuticals is trading 5% down
Atea Pharmaceuticals is trading 5.18% down at $4.94 on October 1, 2026; no specific reason for the decline has been confirmed. - No new company announcement or...
🔴 Atea Pharmaceuticals is trading 5% down today
Atea Pharmaceuticals is trading 5.14% lower at $5.35, with no clear company-specific catalyst identified for September 23, 2026. - Recent positive developments...
🔴 Atea Pharmaceuticals is trading 5.81% down today amid broader market weakness
Atea Pharmaceuticals is trading 5.81% down at $5.35, with broader U.S. markets also lower amid geopolitical and energy-price concerns. - No company-specific...
🔴 Atea Pharmaceuticals is trading 10.45% down today in pre-market — no clear company-specific catalyst identified
Atea Pharmaceuticals is trading 10.45% down at $4.80, with no clear company-specific catalyst identified for August 31, 2026. - The latest identified company...
🔴 Atea Pharmaceuticals is trading 6.35% down today in pre-market
Atea Pharmaceuticals is trading 6.35% down now at $5.02 after no clear company-specific catalyst was identified for the August 31, 2026 pre-market decline. -...
🔴 Atea Pharmaceuticals is trading 17.43% down in pre-market with no company-specific catalyst identified
Atea Pharmaceuticals is trading at $4.50, down 17.43%, with no new company-specific catalyst found to explain the decline. - Latest identified announcement:...
🔴 Atea Pharmaceuticals is trading 10.71% down in pre-market with no clear company-specific catalyst identified
Atea Pharmaceuticals is trading 10.71% down at $4.92 after no clear company-specific catalyst was identified for August 25, 2026. - The latest official...
🟢 Atea Pharmaceuticals rises 5.5% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Atea Pharmaceuticals is trading 5% up today after BEM/RZR met Phase 3 HCV endpoint
Atea Pharmaceuticals is trading 5.14% up now at $5.32 after investors digested August 12, 2026, earnings and encouraging hepatitis C trial data. - Reported a...
Atea Pharmaceuticals second quarter 2026 loss of $0.41 per share beat estimates by $0.15
Atea Pharmaceuticals reported zero revenue for the second quarter of 2026, which is consistent with its status as a clinical-stage biopharmaceutical company....
Atea Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
Atea Pharmaceuticals is expected to report a Q2 2026 consensus loss of $0.56 per share on $0.00 in revenue, with its current stock price of approximately $4.61...
🟢 Atea Pharmaceuticals is trading 5% up today amid broader biotech rally
Atea Pharmaceuticals is trading 5.16% up now at $5.00, alongside a broader biotechnology rally. - Biotech ETF XBI is up 2.09%; sentiment is supported by...
Atea Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Atea Pharmaceuticals is projected to report a Q2 2026 loss of $0.56 per share on zero revenue, with the stock currently trading at $4.12 compared to a $12.00...
🟢 Atea Pharmaceuticals is trading 6.4% up today as shares extend rebound amid broader market gains
Atea Pharmaceuticals is trading 6.4% up today at $4.92 as shares extend a rebound from a recent sell-off amid a broader market rally. • The stock is...
🟢 Atea Pharmaceuticals is trading 5.3% up today on a partial snap-back after a sharp decline
Atea Pharmaceuticals is trading 5.3% up at $4.75 as the stock rebounds from a sharp 12.2% decline on July 28. • The previous sell-off occurred on no...